Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers

Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers

•A close follow-up of vaccinees remains crucial to confirm both safety and long-lasting immune protection.•Three months after vaccination, we confirm a very high efficacy and a persistence of anti-spike antibodies.•The antibody decrease observed in some seronegative participants argues for an additi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infection 2021-09, Vol.83 (3), p.381-412
Hauptverfasser: Tré-Hardy, Marie, Cupaiolo, Roberto, Wilmet, Alain, Beukinga, Ingrid, Blairon, Laurent
Format: Artikel
Sprache:eng
Schlagworte:
2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
COVID-19
COVID-19 Vaccines
Efficacy
Health Personnel
Humans
Immunogenicity
Immunogenicity, Vaccine
Letter to the Editor
mRNA-1273 vaccine
SARS-CoV-2
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•A close follow-up of vaccinees remains crucial to confirm both safety and long-lasting immune protection.•Three months after vaccination, we confirm a very high efficacy and a persistence of anti-spike antibodies.•The antibody decrease observed in some seronegative participants argues for an additional dose of vaccine for this specific subgroup.
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2021.06.017